Simplify Asset Management Inc. Boosts Stock Holdings in AbbVie Inc. $ABBV

Simplify Asset Management Inc. grew its holdings in AbbVie Inc. (NYSE:ABBV) by 100.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,883 shares of the company’s stock after purchasing an additional 18,499 shares during the period. AbbVie comprises about 0.2% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 15th biggest holding. Simplify Asset Management Inc.’s holdings in AbbVie were worth $8,540,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Marshall & Sullivan Inc. WA bought a new position in AbbVie during the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the second quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in AbbVie in the 2nd quarter worth approximately $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of a number of research reports. Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Wells Fargo & Company boosted their price target on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Morgan Stanley raised their price objective on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Trading Down 0.5%

ABBV stock opened at $229.63 on Wednesday. The company has a market capitalization of $405.84 billion, a price-to-earnings ratio of 173.96, a PEG ratio of 1.31 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The business has a 50 day simple moving average of $226.67 and a two-hundred day simple moving average of $213.27.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the business posted $3.00 earnings per share. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.